These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 25625854)

  • 1. Fragment-based designing for the generation of novel leads against BACE1.
    Das S; Chakraborty S; Basu S
    Cent Nerv Syst Agents Med Chem; 2015; 15(1):52-64. PubMed ID: 25625854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-Based Survey of the Binding Modes of BACE1 Inhibitors.
    Hu H; Chen Z; Xu X; Xu Y
    ACS Chem Neurosci; 2019 Feb; 10(2):880-889. PubMed ID: 30540177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Computational modelling of potent β-secretase (BACE1) inhibitors towards Alzheimer's disease treatment.
    Ugbaja SC; Sanusi ZK; Appiah-Kubi P; Lawal MM; Kumalo HM
    Biophys Chem; 2021 Mar; 270():106536. PubMed ID: 33387910
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polymethoxyflavones: Novel β-Secretase (BACE1) Inhibitors from Citrus Peels.
    Youn K; Yu Y; Lee J; Jeong WS; Ho CT; Jun M
    Nutrients; 2017 Sep; 9(9):. PubMed ID: 28869548
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conformational transition in the substrate binding domain of β-secretase exploited by NMA and its implication in inhibitor recognition: BACE1-myricetin a case study.
    Chakraborty S; Kumar S; Basu S
    Neurochem Int; 2011 Jul; 58(8):914-23. PubMed ID: 21354237
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Computational analysis of BACE1-ligand complex crystal structures and linear discriminant analysis for identification of BACE1 inhibitors with anti P-glycoprotein binding property.
    Manoharan P; Chennoju K; Ghoshal N
    J Biomol Struct Dyn; 2018 Jan; 36(1):262-276. PubMed ID: 28081663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of β-site amyloid precursor protein cleaving enzyme 1 and cholinesterases by pterosins via a specific structure-activity relationship with a strong BBB permeability.
    Jannat S; Balupuri A; Ali MY; Hong SS; Choi CW; Choi YH; Ku JM; Kim WJ; Leem JY; Kim JE; Shrestha AC; Ham HN; Lee KH; Kim DM; Kang NS; Park GH
    Exp Mol Med; 2019 Feb; 51(2):1-18. PubMed ID: 30755593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of a BACE1 Binding Peptide Candidate for the Prevention of Amyloid Beta in Alzheimer's Disease.
    Read J; Suphioglu C
    Cell Physiol Biochem; 2019; 53(2):413-428. PubMed ID: 31415717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular docking based virtual screening of natural compounds as potential BACE1 inhibitors: 3D QSAR pharmacophore mapping and molecular dynamics analysis.
    Kumar A; Roy S; Tripathi S; Sharma A
    J Biomol Struct Dyn; 2016; 34(2):239-49. PubMed ID: 25707809
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conformational dynamics of cathepsin D and binding to a small-molecule BACE1 inhibitor.
    Ellis CR; Tsai CC; Lin FY; Shen J
    J Comput Chem; 2017 Jun; 38(15):1260-1269. PubMed ID: 28370344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tyramine fragment binding to BACE-1.
    Kuglstatter A; Stahl M; Peters JU; Huber W; Stihle M; Schlatter D; Benz J; Ruf A; Roth D; Enderle T; Hennig M
    Bioorg Med Chem Lett; 2008 Feb; 18(4):1304-7. PubMed ID: 18226904
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is BACE1 a suitable therapeutic target for the treatment of Alzheimer's disease? Current strategies and future directions.
    Klaver DW; Wilce MC; Cui H; Hung AC; Gasperini R; Foa L; Small DH
    Biol Chem; 2010 Aug; 391(8):849-59. PubMed ID: 20731541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Virtual screening and structure-based discovery of indole acylguanidines as potent β-secretase (BACE1) inhibitors.
    Zou Y; Li L; Chen W; Chen T; Ma L; Wang X; Xiong B; Xu Y; Shen J
    Molecules; 2013 May; 18(5):5706-22. PubMed ID: 23681056
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular insights into the inhibitory mechanism of bi-functional bis-tryptoline triazole against β-secretase (BACE1) enzyme.
    Narang SS; Goyal D; Goyal B
    Amino Acids; 2019 Nov; 51(10-12):1593-1607. PubMed ID: 31654211
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Screening and Elucidation of Selected Natural Compounds for Anti- Alzheimer's Potential Targeting BACE-1 Enzyme: A Case Computational Study.
    Ahmad SS; Akhtar S; Danish Rizvi SM; Kamal MA; Sayeed U; Khan MKA; Siddiqui MH; Arif JM
    Curr Comput Aided Drug Des; 2017 Nov; 13(4):311-318. PubMed ID: 28413992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A PM7 dynamic residue-ligand interactions energy landscape of the BACE1 inhibitory pathway by hydroxyethylamine compounds. Part I: The flap closure process.
    Gueto-Tettay C; Martinez-Consuegra A; Zuchniarz J; Gueto-Tettay LR; Drosos-Ramírez JC
    J Mol Graph Model; 2017 Sep; 76():274-288. PubMed ID: 28746905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. P-glycoprotein efflux and other factors limit brain amyloid beta reduction by beta-site amyloid precursor protein-cleaving enzyme 1 inhibitors in mice.
    Meredith JE; Thompson LA; Toyn JH; Marcin L; Barten DM; Marcinkeviciene J; Kopcho L; Kim Y; Lin A; Guss V; Burton C; Iben L; Polson C; Cantone J; Ford M; Drexler D; Fiedler T; Lentz KA; Grace JE; Kolb J; Corsa J; Pierdomenico M; Jones K; Olson RE; Macor JE; Albright CF
    J Pharmacol Exp Ther; 2008 Aug; 326(2):502-13. PubMed ID: 18499745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rational Design of Novel 1,3-Oxazine Based β-Secretase (BACE1) Inhibitors: Incorporation of a Double Bond To Reduce P-gp Efflux Leading to Robust Aβ Reduction in the Brain.
    Fuchino K; Mitsuoka Y; Masui M; Kurose N; Yoshida S; Komano K; Yamamoto T; Ogawa M; Unemura C; Hosono M; Ito H; Sakaguchi G; Ando S; Ohnishi S; Kido Y; Fukushima T; Miyajima H; Hiroyama S; Koyabu K; Dhuyvetter D; Borghys H; Gijsen HJM; Yamano Y; Iso Y; Kusakabe KI
    J Med Chem; 2018 Jun; 61(12):5122-5137. PubMed ID: 29733614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of BACE1 Activity by a DNA Aptamer in an Alzheimer's Disease Cell Model.
    Liang H; Shi Y; Kou Z; Peng Y; Chen W; Li X; Li S; Wang Y; Wang F; Zhang X
    PLoS One; 2015; 10(10):e0140733. PubMed ID: 26473367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BACE1 Physiological Functions May Limit Its Use as Therapeutic Target for Alzheimer's Disease.
    Barão S; Moechars D; Lichtenthaler SF; De Strooper B
    Trends Neurosci; 2016 Mar; 39(3):158-169. PubMed ID: 26833257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.